Ignite Creation Date:
2025-12-24 @ 7:09 PM
Ignite Modification Date:
2026-01-05 @ 8:41 PM
Study NCT ID:
NCT02450903
Status:
COMPLETED
Last Update Posted:
2021-03-30
First Post:
2015-05-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-08-21
Start Date Type:
ACTUAL
Primary Completion Date:
2017-07-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-05-24
Completion Date Type:
ACTUAL
First Submit Date:
2015-05-08
First Submit QC Date:
None
Study First Post Date:
2015-05-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-05-22
Results First Submit QC Date:
None
Results First Post Date:
2020-12-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-26
Last Update Post Date:
2021-03-30
Last Update Post Date Type:
ACTUAL